Literature DB >> 28060016

Excess respiratory viral infections and low antibody responses among HIV-exposed, uninfected infants.

Adriana Weinberg1, Marisa M Mussi-Pinhata, Qilu Yu, Rachel A Cohen, Volia C Almeida, Fabiana Amaral, Jorge Pinto, Maria L B Teixeira, Regina C M Succi, Laura Freimanis, Jennifer S Read, George Siberry.   

Abstract

OBJECTIVE: HIV-exposed uninfected (HEUs) infants have frequent severe infection, hospitalization, and death. We performed a serologic investigation to determine the role of common childhood respiratory pathogens in the excess incidence of infections in HEUs.
DESIGN: Prospective cohort study of mother-infant pairs.
METHODS: Among 247 HEUs and 88 HIV-unexposed uninfected (HUU) infant-mother pairs, we measured maternal antibodies to respiratory syncytial virus (RSV) and pneumococcus (PNC 1, 5, 6B, 14); infant antibodies to RSV, influenza A (flu), parainfluenza viruses (1, 2, 3), and PNC 1, 5, 6B, and 14 were measured at 0 and 6 months, and antitetanus antibodies at 6 months.
RESULTS: HIV-infected mothers had higher RSV and lower PNC antibody concentrations at delivery than uninfected mothers. Transplacental transfer of maternal antibodies, particularly for RSV, was lower in HEUs compared with HUUs. At birth, HEUs had higher concentrations of anti-RSV antibodies than HUUs, but lower antibodies to the other respiratory agents. At 6 months, HEUs had significantly higher proportions of seroconversions and higher antibody concentrations against parainfluenza viruses 1, 2, and 3. There were no significant differences in seroconversions to flu and RSV, but antibody concentrations to RSV were six-fold lower in HEUs versus HUUs at 6 months. Antibody responses to at least two doses of tetanus vaccine were also six-fold lower in HEUs compared with HUUs.
CONCLUSION: Six-month-old HEUs had a higher incidence of respiratory viral infections than HUUs. In addition to the low passive protection from maternal antibodies, low antibody responses of HEUs may contribute to increased morbidity and mortality.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28060016     DOI: 10.1097/QAD.0000000000001393

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  17 in total

1.  Factors Associated with Lower Respiratory Tract Infections in HIV-Exposed Uninfected Infants.

Authors:  Adriana Weinberg; Marisa M Mussi-Pinhata; Qilu Yu; Rachel A Cohen; Volia C Almeida; Fabiana R Amaral; Laura Freimanis; Donald Robert Harris; Christiana Smith; George Siberry
Journal:  AIDS Res Hum Retroviruses       Date:  2018-04-23       Impact factor: 2.205

2.  Fc Characteristics Mediate Selective Placental Transfer of IgG in HIV-Infected Women.

Authors:  David R Martinez; Youyi Fong; Shuk Hang Li; Fang Yang; Madeleine F Jennewein; Joshua A Weiner; Erin A Harrell; Jesse F Mangold; Ria Goswami; George R Seage; Galit Alter; Margaret E Ackerman; Xinxia Peng; Genevieve G Fouda; Sallie R Permar
Journal:  Cell       Date:  2019-06-13       Impact factor: 41.582

Review 3.  Maternal immunisation to improve the health of HIV-exposed infants.

Authors:  Angela M Bengtson; Alan M Sanfilippo; Brenna L Hughes; David A Savitz
Journal:  Lancet Infect Dis       Date:  2018-12-07       Impact factor: 25.071

4.  HIV-Associated Alterations of the Biophysical Features of Maternal Antibodies Correlate With Their Reduced Transfer Across the Placenta.

Authors:  Sean A Taylor; Shilpee Sharma; Christopher A L Remmel; Beth Holder; Christine E Jones; Arnaud Marchant; Margaret E Ackerman
Journal:  J Infect Dis       Date:  2022-10-17       Impact factor: 7.759

5.  Altered Maternal Antibody Profiles in Women With Human Immunodeficiency Virus Drive Changes in Transplacental Antibody Transfer.

Authors:  Sepideh Dolatshahi; Audrey L Butler; Mark J Siedner; Joseph Ngonzi; Andrea G Edlow; Julian Adong; Madeleine F Jennewein; Caroline Atyeo; Ingrid V Bassett; Drucilla J Roberts; Douglas A Lauffenburger; Galit Alter; Lisa M Bebell
Journal:  Clin Infect Dis       Date:  2022-10-12       Impact factor: 20.999

6.  HIV-exposed-uninfected infants have increased inflammation and monocyte activation.

Authors:  Sahera Dirajlal-Fargo; Marisa M Mussi-Pinhata; Adriana Weinberg; Qilu Yu; Rachel Cohen; D Robert Harris; Emily Bowman; Janelle Gabriel; Manjusha Kulkarni; Nicholas Funderburg; Nahida Chakhtoura; Grace A McComsey
Journal:  AIDS       Date:  2019-04-01       Impact factor: 4.177

7.  B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine.

Authors:  Adriana Weinberg; Jane Lindsey; Ronald Bosch; Deborah Persaud; Paul Sato; Anthony Ogwu; Aida Asmelash; Mutsa Bwakura-Dangarambezi; Benjamin H Chi; Jennifer Canniff; Shahin Lockman; Simani Gaseitsiwe; Sikhulile Moyo; Christiana Elizabeth Smith; Natasha O Moraka; Myron J Levin
Journal:  Front Immunol       Date:  2018-01-19       Impact factor: 7.561

8.  HIV-Exposed Uninfected Infants Have Increased Regulatory T Cells That Correlate With Decreased T Cell Function.

Authors:  Emilie Jalbert; Kayla M Williamson; Miranda E Kroehl; Michael J Johnson; Clare Cutland; Shabir A Madhi; Marta C Nunes; Adriana Weinberg
Journal:  Front Immunol       Date:  2019-03-26       Impact factor: 7.561

9.  Human Immunodeficiency Virus Exposure but Not Early Cytomegalovirus Infection Is Associated With Increased Hospitalization and Decreased Memory T-Cell Responses to Tetanus Vaccine.

Authors:  Christiana Smith; Natasha O Moraka; Maryanne Ibrahim; Sikhulile Moyo; Gloria Mayondi; Betsy Kammerer; Jean Leidner; Simani Gaseitsiwe; Shaobing Li; Roger Shapiro; Shahin Lockman; Adriana Weinberg
Journal:  J Infect Dis       Date:  2020-03-16       Impact factor: 5.226

10.  Immunologic and Virologic Factors Associated With Hospitalization in Human Immunodeficiency Virus-Exposed, Uninfected Infants in the United States.

Authors:  Christiana Smith; Yanling Huo; Kunjal Patel; Kirk Fetters; Shannon Hegemann; Sandra Burchett; Russell Van Dyke; Adriana Weinberg
Journal:  Clin Infect Dis       Date:  2021-09-15       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.